You can seek FDA approval to launch a generic drug before the expiration of ADCIRCA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADCIRCA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADCIRCA:-

You can seek FDA approval to launch a generic drug before the expiration of ANGELIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ANGELIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ANGELIQ:-

You can seek FDA approval to launch a generic drug before the expiration of ATRIPLA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ATRIPLA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ATRIPLA:-

You can seek FDA approval to launch a generic drug before the expiration of BRISDELLE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BRISDELLE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BRISDELLE:-

You can seek FDA approval to launch a generic drug before the expiration of CAMBIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CAMBIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CAMBIA:-

You can seek FDA approval to launch a generic drug before the expiration of CIALIS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CIALIS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CIALIS:-

You can seek FDA approval to launch a generic drug before the expiration of COMPLERA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMPLERA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMPLERA:-

You can seek FDA approval to launch a generic drug before the expiration of DESCOVY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DESCOVY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DESCOVY:-

You can seek FDA approval to launch a generic drug before the expiration of EFFIENT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EFFIENT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EFFIENT:-

You can seek FDA approval to launch a generic drug before the expiration of EMTRIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EMTRIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EMTRIVA:-

You can seek FDA approval to launch a generic drug before the expiration of EVISTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EVISTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EVISTA:-

You can seek FDA approval to launch a generic drug before the expiration of EVOTAZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EVOTAZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EVOTAZ:-

You can seek FDA approval to launch a generic drug before the expiration of EXJADE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EXJADE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EXJADE:-

You can seek FDA approval to launch a generic drug before the expiration of FACTIVE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FACTIVE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FACTIVE:-

You can seek FDA approval to launch a generic drug before the expiration of GENVOYA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GENVOYA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GENVOYA:-

You can seek FDA approval to launch a generic drug before the expiration of JADENU's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JADENU's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JADENU:-

You can seek FDA approval to launch a generic drug before the expiration of LEXIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LEXIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LEXIVA:-

You can seek FDA approval to launch a generic drug before the expiration of LOTREL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LOTREL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LOTREL:-

You can seek FDA approval to launch a generic drug before the expiration of LOVAZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LOVAZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LOVAZA:-

You can seek FDA approval to launch a generic drug before the expiration of NASONEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NASONEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NASONEX:-

You can seek FDA approval to launch a generic drug before the expiration of ODEFSEY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ODEFSEY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ODEFSEY:-

You can seek FDA approval to launch a generic drug before the expiration of OMNARIS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OMNARIS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OMNARIS:-

You can seek FDA approval to launch a generic drug before the expiration of ORENITRAM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ORENITRAM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ORENITRAM:-

You can seek FDA approval to launch a generic drug before the expiration of PREZCOBIX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PREZCOBIX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PREZCOBIX:-

You can seek FDA approval to launch a generic drug before the expiration of PREZISTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PREZISTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PREZISTA:-

You can seek FDA approval to launch a generic drug before the expiration of REMODULIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REMODULIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REMODULIN:-

You can seek FDA approval to launch a generic drug before the expiration of REYATAZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REYATAZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REYATAZ:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of STRIBILD's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STRIBILD's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STRIBILD:-

You can seek FDA approval to launch a generic drug before the expiration of SYMBYAX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SYMBYAX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SYMBYAX:-

You can seek FDA approval to launch a generic drug before the expiration of TRUVADA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRUVADA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRUVADA:-

You can seek FDA approval to launch a generic drug before the expiration of TYKERB's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TYKERB's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TYKERB:-

You can seek FDA approval to launch a generic drug before the expiration of TYVASO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TYVASO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TYVASO:-

You can seek FDA approval to launch a generic drug before the expiration of VELCADE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VELCADE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VELCADE:-

You can seek FDA approval to launch a generic drug before the expiration of VIREAD's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VIREAD's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VIREAD:-

You can seek FDA approval to launch a generic drug before the expiration of YASMIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the YASMIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on YASMIN:-